New data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.